<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article">
 <front>
  <journal-meta>
   <journal-id journal-id-type="publisher-id">
    ojim
   </journal-id>
   <journal-title-group>
    <journal-title>
     Open Journal of Internal Medicine
    </journal-title>
   </journal-title-group>
   <issn pub-type="epub">
    2162-5972
   </issn>
   <issn publication-format="print">
    2162-5980
   </issn>
   <publisher>
    <publisher-name>
     Scientific Research Publishing
    </publisher-name>
   </publisher>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="doi">
    10.4236/ojim.2024.144030
   </article-id>
   <article-id pub-id-type="publisher-id">
    ojim-138208
   </article-id>
   <article-categories>
    <subj-group subj-group-type="heading">
     <subject>
      Articles
     </subject>
    </subj-group>
    <subj-group subj-group-type="Discipline-v2">
     <subject>
      Medicine 
     </subject>
     <subject>
       Healthcare
     </subject>
    </subj-group>
   </article-categories>
   <title-group>
    Thyroid Inflammatory Myofibroblastic Tumor: A Rare Case, Literature Review
   </title-group>
   <contrib-group>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Hamza
      </surname>
      <given-names>
       Sümter
      </given-names>
     </name>
    </contrib>
   </contrib-group> 
   <aff id="affnull">
    <addr-line>
     aDepartment of Internal Medicine, Hematology, Uşak Training and Research Hospital, Uşak, Türkiye
    </addr-line> 
   </aff> 
   <pub-date pub-type="epub">
    <day>
     11
    </day> 
    <month>
     11
    </month>
    <year>
     2024
    </year>
   </pub-date> 
   <volume>
    14
   </volume> 
   <issue>
    04
   </issue>
   <fpage>
    337
   </fpage>
   <lpage>
    342
   </lpage>
   <history>
    <date date-type="received">
     <day>
      30,
     </day>
     <month>
      August
     </month>
     <year>
      2024
     </year>
    </date>
    <date date-type="published">
     <day>
      14,
     </day>
     <month>
      August
     </month>
     <year>
      2024
     </year> 
    </date> 
    <date date-type="accepted">
     <day>
      14,
     </day>
     <month>
      December
     </month>
     <year>
      2024
     </year> 
    </date>
   </history>
   <permissions>
    <copyright-statement>
     © Copyright 2014 by authors and Scientific Research Publishing Inc. 
    </copyright-statement>
    <copyright-year>
     2014
    </copyright-year>
    <license>
     <license-p>
      This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/
     </license-p>
    </license>
   </permissions>
   <abstract>
    Inflammatory myofibroblastic tumor has been referred to by many different names in the past, such as plasma cell granuloma, inflammatory pseudotumor, fibrous histiocytoma, fibroxanthoma, xanthogranuloma. It was first described in the 1930s. It originates from soft tissue. It has low malignancy potential. It is rarely seen. While it is often localized in the lungs, it can rarely be localized in the thyroid gland. Its etiology and pathogenesis are unknown. Diagnosis is based on postoperative immunohistochemical evaluation. Although surgical resection is the main treatment method, there is no standard approach. Recurrence is not expected in general. However, cases of recurrence after a long period of time have also been reported. In this study, a 46-year-old female patient was presented with thyroid inflammatory myofibroblastic tumor that developed after COVID-19. Another notable point in the case is that her mother had myeloma with mutations (changes in chromosomes 11 and 14).
   </abstract>
   <kwd-group> 
    <kwd>
     Inflammatory Myofibroblastic
    </kwd> 
    <kwd>
      Tumor
    </kwd> 
    <kwd>
      Thyroid
    </kwd> 
    <kwd>
      ALK
    </kwd>
   </kwd-group>
  </article-meta>
 </front>
 <body>
  <sec id="s1">
   <title>1. Introduction</title>
   <p>Inflammatory myofibroblastic tumor (IMT) develops as a result of myofibroblast proliferation. It is a rare disease. Most patients present with a mass <xref ref-type="bibr" rid="scirp.138208-1">
     [1]
    </xref>. It can occur in any location in the body, especially in the lungs <xref ref-type="bibr" rid="scirp.138208-2">
     [2]
    </xref>. Etiology and pathogenesis are unknown. Diagnosis is based on histology. The biopsy contains varying amounts of fibroblasts, myofibroblasts, plasma cells, lymphocytes, and eosinophils <xref ref-type="bibr" rid="scirp.138208-3">
     [3]
    </xref>. The picture may be accompanied by fever, weight loss, and laboratory abnormalities <xref ref-type="bibr" rid="scirp.138208-1">
     [1]
    </xref>. Although there is no standard treatment, surgical resection is the primary treatment option <xref ref-type="bibr" rid="scirp.138208-1">
     [1]
    </xref>. Prognosis is variable. The true prevalence of the disease is unknown.</p>
  </sec><sec id="s2">
   <title>2. Case Report</title>
   <p>A 48-year-old female patient was evaluated in the hematology clinic due to swelling in her neck. There was no medical or herbal drug use in her anamnesis. In terms of lymphoproliferative disease, fever, weight loss, night sweats, etc. (B symptom) were not observed. The diagnosis of multiple myeloma in the mother drew attention in terms of family history (The patient’s mother was a myeloma patient with changes in chromosomes 11 and 14 in our hematology clinic). Complete blood count, biochemical values (transaminases, renal function tests), thyroid function tests, thyroglobulin, antithyroid peroxidase, anti-thyroglobulin were within normal range. No pathology was detected in hepatitis (HAV, HBV, HCV), TORCH, EBV, brucella, salmonella tests. No atypical cells were observed in the peripheral blood smear. Ultrasonography performed for a palpable swelling in the neck on physical examination revealed a 21 mm × 12 mm nodule in the left lobe and a 40 mm × 22 mm nodule in the right lobe. Fine needle aspiration biopsy was found to be compatible with thyroiditis. In the evaluation made 3 months later, fine needle aspiration biopsy was repeated to exclude malignancy. However, sufficient results were not obtained. The patient, who did not have B symptom, was re-evaluated with cervical USG approximately 2 months later. In this USG, a 47 mm × 27 mm × 35 mm nodule was detected, almost completely filling the right thyroid lobe and extending to the isthmus. Surgery was recommended to the patient to exclude possible malignancy and right subtotal thyroidectomy was performed. Spindle cells, dense histiocyte aggregates, plasma cells and lymphocytes were seen in the postoperative material. No increase in mitotic activity was observed. Smooth muscle actin(+), CD68(+), TTF1(-) were detected in the sample. The case was diagnosed with thyroid inflammatory myofibroblastic tumor. Because of its rarity, the diagnosis was confirmed in two different centers. ALK rearrangement was found to be negative (<xref ref-type="fig" rid="fig1">
     Figure 1
    </xref>, <xref ref-type="fig" rid="fig2">
     Figure 2
    </xref>). As of September 2024, the patient has been asymptomatic and has been monitored in our clinic for 2 years postoperatively.</p>
   <fig id="fig1" position="float">
    <label>Figure 1</label>
    <caption>
     <title>Figure 1. Pathology result of the patient (confirmed in two different pathology departments).</title>
    </caption>
    <graphic mimetype="image" position="float" xlink:type="simple" xlink:href="https://html.scirp.org/file/1320654-rId14.jpeg?20241217035242" />
   </fig>
   <fig id="fig2" position="float">
    <label>Figure 2</label>
    <caption>
     <title>Figure 2. ALK result of the patient: negative.</title>
    </caption>
    <graphic mimetype="image" position="float" xlink:type="simple" xlink:href="https://html.scirp.org/file/1320654-rId15.jpeg?20241217035242" />
   </fig>
  </sec><sec id="s3">
   <title>3. Discussion</title>
   <p>Inflammatory myofibroblastic tumor (IMT), a rare disorder, was first described in the thoracic region in 1939 <xref ref-type="bibr" rid="scirp.138208-1">
     [1]
    </xref>. In the literature, plasma cell granuloma (PCG) is also called inflammatory pseudotumor (IPT) <xref ref-type="bibr" rid="scirp.138208-3">
     [3]
    </xref>. Although the etiology and pathogenesis are unknown, many factors such as trauma, viruses, inflammation, infection, and abnormal response to prolonged exogenous stimulation have been implicated <xref ref-type="bibr" rid="scirp.138208-1">
     [1]
    </xref> <xref ref-type="bibr" rid="scirp.138208-4">
     [4]
    </xref>. In this case, cervical swelling after covid-19 supports the hypothesis of an abnormal response to infection. Also, the fact that the patient’s mother was a patient with multiple myeloma followed up in our hematology clinic made us think about genetic and/or epigenetic factors in the etiopathogenesis of thyroid inflammatory myofibroblastic tumor. The mother with myeloma diagnosis has t (11; 14) (translocation between chromosome 11 and chromosome 14) (<xref ref-type="fig" rid="fig3">
     Figure 3
    </xref>).</p>
   <fig id="fig3" position="float">
    <label>Figure 3</label>
    <caption>
     <title>Figure 3. t (11:14) mutation of the patient’s mother.</title>
    </caption>
    <graphic mimetype="image" position="float" xlink:type="simple" xlink:href="https://html.scirp.org/file/1320654-rId16.jpeg?20241217035242" />
   </fig>
   <p>Inflammatory myofibroblastic tumors are more commonly localized in the lungs, but may also be located in any organ <xref ref-type="bibr" rid="scirp.138208-3">
     [3]
    </xref>. It presents with a massive lesion and presenting symptoms may vary according to localization <xref ref-type="bibr" rid="scirp.138208-1">
     [1]
    </xref>. According to the World Health Organization, IMT is defined as a low-grade malignant tumor <xref ref-type="bibr" rid="scirp.138208-1">
     [1]
    </xref>. Although it can be seen at any age, it peaks in children and adolescents <xref ref-type="bibr" rid="scirp.138208-1">
     [1]
    </xref>. More than half of the cases are under the age of 40 <xref ref-type="bibr" rid="scirp.138208-5">
     [5]
    </xref>. While IMT is generally seen with equal frequency across genders and races, there is a female predominance in the identified thyroid IMT cases <xref ref-type="bibr" rid="scirp.138208-6">
     [6]
    </xref>.</p>
   <p>Histology is essential for diagnosis <xref ref-type="bibr" rid="scirp.138208-1">
     [1]
    </xref>. The biopsy contains varying amounts of fibroblasts, myofibroblasts, plasma cells, lymphocytes, and eosinophils <xref ref-type="bibr" rid="scirp.138208-1">
     [1]
    </xref>. There are 3 histological patterns: mixoid, vascular, inflammatory pattern, compact spindle cell pattern, dense fibrotic pattern <xref ref-type="bibr" rid="scirp.138208-3">
     [3]
    </xref>. Immunohistochemically, vimentin is diffusely positive, and myogenic antibodies smooth muscle actin and muscle-specific actin are localized or diffusely positive <xref ref-type="bibr" rid="scirp.138208-1">
     [1]
    </xref>. ALK positivity is seen in 50% - 70% of cases <xref ref-type="bibr" rid="scirp.138208-1">
     [1]
    </xref>. S100, myoglobin, CD21, CD23, CD34, CD117, caldesmon are frequently negative <xref ref-type="bibr" rid="scirp.138208-1">
     [1]
    </xref>.</p>
   <p>While IMT cases in the head and neck region constitute approximately 5% of all cases, IMT cases, especially those located in the thyroid, are much less common <xref ref-type="bibr" rid="scirp.138208-1">
     [1]
    </xref>-<xref ref-type="bibr" rid="scirp.138208-3">
     [3]
    </xref>. According to a study published in 2022, the total number of thyroid IMT (PCG/IMT/IPT) cases in the English literature is 25. Of these cases, 8 were male and 17 were female. This is the third thyroid IMT case from Turkey after the two cases published by Deniz et al. in 2008 <xref ref-type="bibr" rid="scirp.138208-7">
     [7]
    </xref>.</p>
   <p>The primary treatment for IMT located in the head and neck is surgery <xref ref-type="bibr" rid="scirp.138208-1">
     [1]
    </xref>. If surgical resection cannot be performed completely, recurrence may occur at a rate of up to 50% and metastasis is less than 2% <xref ref-type="bibr" rid="scirp.138208-1">
     [1]
    </xref>. In 2017, only one of the 20 thyroid IMT cases reported recurrence, and this patient received thyroid radiotherapy and oral steroid treatment <xref ref-type="bibr" rid="scirp.138208-3">
     [3]
    </xref>. It has been stated that ALK (+) may be effective in this recurrence <xref ref-type="bibr" rid="scirp.138208-2">
     [2]
    </xref>.</p>
   <p>In general, the prognosis is variable. It may remain stable or grow slowly or even regress spontaneously <xref ref-type="bibr" rid="scirp.138208-8">
     [8]
    </xref>-<xref ref-type="bibr" rid="scirp.138208-10">
     [10]
    </xref>. In most cases, recurrence is not expected after surgery <xref ref-type="bibr" rid="scirp.138208-11">
     [11]
    </xref> <xref ref-type="bibr" rid="scirp.138208-12">
     [12]
    </xref>. However, a case of recurrence 11 years after surgery has also been described <xref ref-type="bibr" rid="scirp.138208-13">
     [13]
    </xref> <xref ref-type="bibr" rid="scirp.138208-14">
     [14]
    </xref>. Some studies have stated that ALK (+) indicates a poor prognosis for patients and that ALK inhibitors such as crizotinib may be promising in the treatment of these cases <xref ref-type="bibr" rid="scirp.138208-1">
     [1]
    </xref> <xref ref-type="bibr" rid="scirp.138208-3">
     [3]
    </xref>.</p>
  </sec><sec id="s4">
   <title>4. Conclusion</title>
   <p>Inflammatory myofibroblastic tumor is a rare disease and can present as a mass lesion at any location in the body. Thyroid localization is as rare as possible. Etiology, pathogenesis and frequency are unknown. It can be seen at any age. Histology (immunological histochemistry) is essential for diagnosis. The prognosis is generally good after surgery. It usually does not require further treatment such as chemotherapy or radiotherapy. However, it should be kept in mind that it may relapse long after the diagnosis.</p>
  </sec>
 </body><back>
  <ref-list>
   <title>References</title>
   <ref id="scirp.138208-ref1">
    <label>1</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Zhao, J., Han, D., Gao, M., Liu, M., Feng, C., Chen, G., et al. (2020) Inflammatory Myofibroblastic Tumor of the Neck with Thyroid Invasion: A Case Report and Literature Review. Gland Surgery, 9, 1042-1047. &gt;https://doi.org/10.21037/gs-20-355 
    </mixed-citation>
   </ref>
   <ref id="scirp.138208-ref2">
    <label>2</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Duan, J. and Wang, Y. (2017) A Case Report of Recurrent Thyroid Inflammatory Myofibroblastic Tumor and Its Metastasis in Soft Tissue. Medicine, 96, e8485. &gt;https://doi.org/10.1097/md.0000000000008485 
    </mixed-citation>
   </ref>
   <ref id="scirp.138208-ref3">
    <label>3</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Li, C., Wu, X., Wang, J., Wang, K., Zhang, S., Huang, J., et al. (2020) ALK-1-Positive Inflammatory Myofibroblastic Tumor of the Thyroid Complicated by Hashimoto’s Thyroiditis: Report of a Rare Case and a Literature Review. Diagnostic Pathology, 15, Article No. 58. &gt;https://doi.org/10.1186/s13000-020-00966-4 
    </mixed-citation>
   </ref>
   <ref id="scirp.138208-ref4">
    <label>4</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Matsubara, O., Tan-Liu, N.S., Kenney, R.M. and Mark, E.J. (1988) Inflammatory Pseudotumors of the Lung: Progression from Organizing Pneumonia to Fibrous Histiocytoma or to Plasma Cell Granuloma in 32 Cases. Human Pathology, 19, 807-814. &gt;https://doi.org/10.1016/s0046-8177(88)80264-8 
    </mixed-citation>
   </ref>
   <ref id="scirp.138208-ref5">
    <label>5</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Weinberger, S.E. (2023) Uptodate, Uptodate, Inflammatory Myofibroblastic Tumor (Plasma Cell Granuloma) of the Lung. 
    </mixed-citation>
   </ref>
   <ref id="scirp.138208-ref6">
    <label>6</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Demirhan, O., Ozkara, S., Yaman, M. and Kaynak, K. (2013) A Rare Benign Tumor of the Lung: Inflammatory Myofibroblastic Tumor—Case Report. Respiratory Medicine Case Reports, 8, 32-35. &gt;https://doi.org/10.1016/j.rmcr.2013.01.001 
    </mixed-citation>
   </ref>
   <ref id="scirp.138208-ref7">
    <label>7</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Deniz, K., Patirogˇlu, T.E. and Okten, T. (2008) Plasma Cell Granuloma of the Thyroid. Case Report. Journal of Pathology, Microbiology and Immunology, 116, 167-172. &gt;https://doi.org/10.1111/j.1600-0463.2008.00827.x 
    </mixed-citation>
   </ref>
   <ref id="scirp.138208-ref8">
    <label>8</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Mandelbaum, I., Brashear, R.E. and Hull, M.T. (1981) Surgical Treatment and Course of Pulmonary Pseudotumor (Plasma Cell Granuloma). The Journal of Thoracic and Cardiovascular Surgery, 82, 77-82. &gt;https://doi.org/10.1016/s0022-5223(19)39390-0 
    </mixed-citation>
   </ref>
   <ref id="scirp.138208-ref9">
    <label>9</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Kim, J.H., Cho, J.H., Park, M.S., Chung, J.H., Lee, J.G., Kim, Y.S., et al. (2002) Pulmonary Inflammatory Pseudotumor—A Report of 28 Cases. The Korean Journal of Internal Medicine, 17, 252-258. &gt;https://doi.org/10.3904/kjim.2002.17.4.252 
    </mixed-citation>
   </ref>
   <ref id="scirp.138208-ref10">
    <label>10</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Gal, A.A., Koss, M.N., McCarthy, W.F. and Hochholzer, L. (1994) Prognostic Factors in Pulmonary Fibrohistiocytic Lesions. Cancer, 73, 1817-1824. &gt;https://doi.org/10.1002/1097-0142(19940401)73:7&lt;1817::aid-cncr2820730708&gt;3.0.co;2-k 
    </mixed-citation>
   </ref>
   <ref id="scirp.138208-ref11">
    <label>11</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Fabre, D., Fadel, E., Singhal, S., de Montpreville, V., Mussot, S., Mercier, O., et al. (2009) Complete Resection of Pulmonary Inflammatory Pseudotumors Has Excellent Long-Term Prognosis. The Journal of Thoracic and Cardiovascular Surgery, 137, 435-440. &gt;https://doi.org/10.1016/j.jtcvs.2008.07.009 
    </mixed-citation>
   </ref>
   <ref id="scirp.138208-ref12">
    <label>12</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Chen, C.-H., Huang, W., et al. (2008) Surgical Outcome of Inflammatory Pseudotumor in the Lung. The Thoracic and Cardiovascular Surgeon, 56, 214-216. &gt;https://doi.org/10.1055/s-2007-989340 
    </mixed-citation>
   </ref>
   <ref id="scirp.138208-ref13">
    <label>13</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Weinberg, P.B., Bromberg, P.A. and Askin, F.B. (1987) “Recurrence” of a Plasma Cell Granuloma 11 Years after Initial Resection. Southern Medical Journal, 80, 519-521. &gt;https://doi.org/10.1097/00007611-198704000-00028 
    </mixed-citation>
   </ref>
   <ref id="scirp.138208-ref14">
    <label>14</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Cerfolio, R.J., Allen, M.S., Nascimento, A.G., Deschamps, C., Trastek, V.F., Miller, D.L., et al. (1999) Inflammatory Pseudotumors of the Lung. The Annals of Thoracic Surgery, 67, 933-936. &gt;https://doi.org/10.1016/s0003-4975(99)00155-1
    </mixed-citation>
   </ref>
  </ref-list>
 </back>
</article>